dr. daniel petrylak discusses the future of abiraterone acetate
Published 12 years ago • 450 plays • Length 0:41Download video MP4
Download video MP3
Similar videos
-
1:43
dr. petrylak discusses sequencing prostate cancer therapies
-
1:08
dr. daniel petrylak explains the correlation between immune response to sipuleucel-t and survival
-
0:47
dr. daniel petrylak describes the clinical investigation of prostvac in prostate cancer
-
1:10
dr. daniel petrylak discusses chemotherapy in prostate cancer
-
1:03
dr. daniel petrylak on the role of enzalutamide in prostate cancer
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
9:41
can pirads determine treatment?, detecting pelvic lymph nodes
-
1:23:57
dr. perler
-
1:11
dr. daniel petrylak on orteronel (tak-700) plus docetaxel in prostate cancer
-
0:34
dr. petrylak discusses custirsen as a potential treatment for prostate cancer
-
0:44
dr. petrylak on the results of the phase ii stride study
-
1:11
dr. daniel petrylak on sipuleucel-t delaying time to first opioid use
-
0:54
dr. ryan on the long term safety of abiraterone use
-
1:21
dr. petrylak explains prostate cancer clinical trial difficulties
-
1:14
dr. robert dreicer discusses using abiraterone acetate
-
0:47
dr. petrylak on the recent developments in prostate cancer
-
1:06
dr. daniel petrylak on early trials for a new urothelial bladder cancer treatment
-
1:05
dr. petrylak on psma adc for patients with mcrpc
-
1:14
dr. ryan discusses the unblinding of the cou-aa-302 trial
-
1:22
dr. charles ryan discusses neoadjuvant abiraterone acetate
-
0:25
daniel p. petrylak, md, on the role of dna repair gene mutations in metastatic urothelial carcinoma
-
0:57
dr. petrylak discusses the isotope radium-223